Roche Agrees To Purchase Part Of COVID-19 Test Player LumiraDx Diagnostics Platform For $295M
Roche Agrees To Purchase Part Of COVID-19 Test Player LumiraDx Diagnostics Platform For $295M
Friday, LumiraDx Limited (NASDAQ:LMDX) appointed joint administrators for two subsidiaries. The administrators signed a definitive agreement to sell certain companies of LumiraDx related to LumiraDx's point-of-care technology to Roche Holdings AG (OTC: RHHBY).
周五，LumiraDX Limited（纳斯达克股票代码：LMDX）任命了两家子公司的联合管理人。管理人员签署了一项最终协议，将某些与LumiraDX的即时医疗技术相关的LumiraDX公司出售给罗氏控股股份公司（场外交易代码：RHHBY）。
Separately, LumiraDx appointed Andrew Johnson, Lisa Rickelton, and Lindsay Hallam of FTI Consulting as joint administrators of two subsidiaries, LumiraDx Group Limited and LumiraDx International Limited, which together hold substantially all of the assets of the LumiraDx group.
另外，LumiraDX任命FTI Consulting的安德鲁·约翰逊、丽莎·里克尔顿和林赛·哈勒姆为两家子公司LumiradX集团有限公司和LumiradX国际有限公司的联合管理人，这两家子公司共持有LumiradX集团的几乎所有资产。
Roche will pay $295 million and an additional payment of up to $55 million for the reimbursement of amounts to fund the point-of-care diagnostics platform business until the closing of the acquisition.
在收购完成之前，罗氏将支付2.95亿美元，并额外支付高达5500万美元的款项，用于报销为即时诊断平台业务提供资金的款项。
The completion of the transaction is subject to certain conditions, including antitrust and regulatory approvals, and is currently expected to close by mid-2024.
该交易的完成取决于某些条件，包括反垄断和监管部门的批准，目前预计将于2024年中期完成。
It is anticipated that all sale proceeds will be used to repay certain amounts outstanding under the loan agreement and that there will be no distribution to the company or its shareholders.
预计所有出售收益将用于偿还贷款协议下的某些未偿还款项，并且不会向公司或其股东进行分配。
The appointment of the Administrators and sale to Roche represents the culmination of LumiraDx's previously announced strategic review process.
管理人员的任命和出售给罗氏代表了LumiraDX先前宣布的战略审查程序的高潮。
Price Action: LMDX shares are down 22.30% at $0.49 during the premarket session on the last check Tuesday.
价格走势：周二最后一次盘前交易中，LMDX股价下跌22.30％，至0.49美元。